V940 (mRNA-4157)
Adjuvant Melanoma
Phase 3Active
Key Facts
About Merck
Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.
View full company profileOther Adjuvant Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 3 |